1 |
NCT03462888 |
Recruiting |
Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients |
|
|
Observational |
|
- Centre Oscar Lambret
- Centre Leon Berard
- Société Française de lutte contre les Cancers et les leucémies de l’Enfant et l’adolescent
- (and 2 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Progression-free survival
- Clinical parameters of RMS in AYA
- Biological parameters of RMS in AYA
- (and 2 more...)
|
150 |
All |
15 Years to 25 Years (Child, Adult) |
NCT03462888 |
RMS-AJA-1701 |
RMS-AJA-1701 |
February 23, 2018 |
September 2018 |
September 2018 |
March 13, 2018 |
April 4, 2018 |
|
- Centre Oscar Lambret
Lille, France - CHU de Nancy
Nancy, France - Centre de Lacassagne à
Nice, France - Institut Claudius Regaud
Toulouse, France
|
2 |
NCT01871766 |
Recruiting |
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy |
|
- Drug: Vincristine
- Drug: Dactinomycin
- Drug: Cyclophosphamide
- (and 13 more...)
|
Interventional |
Phase 2 |
- St. Jude Children's Research Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (intermediate risk arm)
- Event-free survival (high risk arm)
- Rate of false negative and false positive the sentinel lymph node procedure (low and intermediate risk arms)
- (and 8 more...)
|
100 |
All |
up to 21 Years (Child, Adult) |
NCT01871766 |
RMS13 NCI-2013-00913 |
|
December 4, 2013 |
June 2021 |
June 2024 |
June 7, 2013 |
February 26, 2018 |
|
- University of Florida Proton Therapy Institute
Jacksonville, Florida, United States - Nemours Children's Clinic
Jacksonville, Florida, United States - St. Jude Children's Research Hospital
Memphis, Tennessee, United States - Cook Children's Medical Center
Fort Worth, Texas, United States
|
3 |
NCT00592592 |
Recruiting |
Proton RT for the Treatment of Pediatric Rhabdomyosarcoma |
|
- Radiation: Proton Beam Radiation
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- M.D. Anderson Cancer Center
- Brigham and Women's Hospital
- (and 4 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Late toxicity
- Acute toxicity
- Dosimetric comparison
- Local Control
|
110 |
All |
up to 21 Years (Child, Adult) |
NCT00592592 |
04-188 P01CA021239 |
|
October 2004 |
June 2020 |
June 2020 |
January 14, 2008 |
October 17, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
4 |
NCT01355445 |
Recruiting |
Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma |
|
- Drug: Vincristine, Irinotecan
- Drug: Vincristine, Irinotecan, Temozolomide
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumour response and progression in each treatment arm.
- To assess the duration of tumor response in each treatment arm
- To determine the time to tumor progression in each treatment arm
- (and 3 more...)
|
120 |
All |
6 Months to 50 Years (Child, Adult) |
NCT01355445 |
VIT-0910 2010-023135-42 |
VIT-0910 |
January 2012 |
December 2017 |
September 2021 |
May 18, 2011 |
July 21, 2017 |
|
- Centre Hospitalier Universitaire Nord
Amiens, France - Hôpital des Enfants, Groupe Hospitalier Pellegrin
Bordeaux, France - CHU Morvan
Brest, France - (and 17 more...)
|
5 |
NCT03296371 |
Recruiting |
Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma |
- Alveolar Rhabdomyosarcoma
- Embryonal Rhabdomyosarcoma
|
- Procedure: Biospecimen Collection
- Other: Laboratory Biomarker Analysis
- Other: Questionnaire Administration
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
|
- Frequency of de novo germline mutations in cancer predisposition genes
- Novel recurrent de novo germline mutations
|
900 |
All |
up to 50 Years (Child, Adult) |
NCT03296371 |
AEPI15N1 NCI-2017-01665 |
|
January 23, 2017 |
May 1, 2021 |
May 2021 |
September 28, 2017 |
January 23, 2018 |
|
- Childrens Oncology Group
Philadelphia, Pennsylvania, United States - Baylor College of Medicine
Houston, Texas, United States
|
6 |
NCT03041701 |
Recruiting |
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma |
- Rhabdomyosarcoma
- Rhabdomyosarcoma- Alveolar
- Rhabdomyosarcoma-Embryonal
|
- Drug: Dasatinib
- Drug: Ganitumab
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: To determine the safe dose of dasatinib when given with ganitumab in patients with relapsed or refractory embryonal or alveolar RMS.
- Phase II: Number of patients who experience an objective clinical response (CR or PR) when treated with ganitumab plus dasatinib
- To assess the PFS in patients receiving this combination.
- (and 2 more...)
|
24 |
All |
2 Years to 99 Years (Child, Adult, Senior) |
NCT03041701 |
170049 17-C-0049 |
|
July 7, 2017 |
October 31, 2021 |
October 31, 2021 |
February 3, 2017 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
7 |
NCT02509598 |
Recruiting |
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping |
|
- Drug: Tc99m tilmanocept
- Drug: Vital Blue Dye (optional)
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Incidence of adverse events in pediatric subjects with melanoma, rhabdomyosarcoma, or other solid tumors who are undergoing lymph node mapping
- Changes in vital signs
- Changes in laboratory parameters
- (and 16 more...)
|
27 |
All |
up to 17 Years (Child) |
NCT02509598 |
NAV3-18 |
|
August 2015 |
June 2021 |
June 2021 |
July 28, 2015 |
January 17, 2018 |
|
- Nemours Children's Hopsital
Orlando, Florida, United States - Children's Hospital Medical Center
Cincinnati, Ohio, United States - Nationwide Children's Hospital
Columbus, Ohio, United States - Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
8 |
NCT03111069 |
Not yet recruiting |
Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children |
- Malignant Neoplasms of Mesothelial and Soft Tissue
- Rhabdomyosarcoma, Pelvic
- Rhabdomyosarcoma, Abdominal
|
- Procedure: Abdominal Surgery
- Drug: Doxorubicin
- Radiation: Intra-Operative Radiation
|
Interventional |
Phase 1 |
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Progression of Disease
|
28 |
All |
1 Year to 6 Years (Child) |
NCT03111069 |
2016-0756 |
|
April 2018 |
April 2021 |
April 2021 |
April 12, 2017 |
January 17, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
9 |
NCT03441360 |
Recruiting |
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) |
- Relapsed/Refractory Rhabdomyosarcoma
- Non-rhabdomyosarcoma Soft Tissue Sarcoma
- Ewing Sarcoma
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response
- Progression-free survival (PFS)
- Number of participants with any treatment-emergent (TE) serious adverse event (SAE)
- (and 6 more...)
|
30 |
All |
12 Months to 18 Years (Child, Adult) |
NCT03441360 |
E7389-G000-223 |
|
January 23, 2018 |
June 2020 |
January 2021 |
February 21, 2018 |
March 15, 2018 |
|
- Children's of Alabama
Birmingham, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - Loma Linda University Cancer Center
Loma Linda, California, United States - (and 36 more...)
|
10 |
NCT02567435 |
Recruiting |
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma |
- Alveolar Rhabdomyosarcoma
- Botryoid-Type Embryonal Rhabdomyosarcoma
- Embryonal Rhabdomyosarcoma
- (and 4 more...)
|
- Drug: Cyclophosphamide
- Biological: Dactinomycin
- Drug: Irinotecan Hydrochloride
- (and 5 more...)
|
Interventional |
Phase 3 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS)
- Overall survival (OS)
|
337 |
All |
up to 40 Years (Child, Adult) |
NCT02567435 |
NCI-2015-01644 ARST1431 U10CA180886 |
|
May 23, 2016 |
November 1, 2022 |
|
October 5, 2015 |
April 17, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 298 more...)
|
11 |
NCT02372006 |
Recruiting |
Trial of Afatinib in Pediatric Tumours |
- Neuroectodermal Tumors
- Rhabdomyosarcoma
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response - expansion part/Phase II part
- Dose Limiting Toxicity during first course - dose finding part
- Pharmacokinetics: AUCtau,ss - dose finding part
- (and 12 more...)
|
55 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02372006 |
1200.120 2014-002123-10 |
|
April 29, 2015 |
February 15, 2019 |
February 15, 2019 |
February 26, 2015 |
April 18, 2018 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States - The University Of Texas at Houston
Houston, Texas, United States - University of Wisconsin
Madison, Wisconsin, United States - (and 24 more...)
|
12 |
NCT00876031 |
Recruiting |
Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma |
|
- Drug: trofosfamide, idarubicin, etoposide
|
Interventional |
Phase 3 |
- University Hospital Tuebingen
- Cooperative Weichteilsarkom Study Group
- Deutsche Kinderkrebsstiftung
- (and 5 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- event free survival (EFS)
- Overall survival
|
320 |
All |
6 Months to 21 Years (Child, Adult) |
NCT00876031 |
CWS-2007-HR 4033024 (BfArM) 293/2007AMG1 (Ethikkommission) 2007-001478-10 A2007/14 (Kinderkrebsstiftung) 498 (Krebsstudienregister) |
CWS-2007-HR |
July 2009 |
July 2019 |
July 2024 |
April 6, 2009 |
February 1, 2018 |
|
- Krankenhaus der Stadt Dornbirn
Dornbirn, Austria - Universitätsklinik für Kinder- und Jugendheilkunde
Graz, Austria - Universitätsklinik für Kinder- und Jugendheilkunde
Innsbruck, Austria - (and 84 more...)
|
13 |
NCT02581384 |
Recruiting |
Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors |
- Ewing Sarcoma
- Rhabdomyosarcoma
- Wilms Tumor
- (and 8 more...)
|
- Radiation: Stereotactic Body Radiotherapy (SBRT)
|
Interventional |
Phase 1 Phase 2 |
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity
- Overall Response
- Best Overall Response
|
25 |
All |
up to 21 Years (Child, Adult) |
NCT02581384 |
15-278 |
|
May 2016 |
February 2019 |
February 2023 |
October 21, 2015 |
February 2, 2018 |
|
- Boston Children's Hospital
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
14 |
NCT02748135 |
Recruiting |
A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma |
- Relapsed or Refractory Medulloblastoma (MB) (Part A: Also Include Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS))
|
- Drug: TB-403 20mg/kg
- Drug: TB-403 50mg/kg
- Drug: TB-403 100mg/kg
- Drug: TB-403 ≤175mg/kg
|
Interventional |
Phase 1 Phase 2 |
- Oncurious NV
- BioInvent International AB
- Beat Childhood Cancer
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- In Part A, the primary safety endpoint will be the determination of the maximum tolerated dose (MTD) / study maximum dose (SMD) based on the occurrence of dose-limiting toxicities (DLTs) during the 28-day DLT assessment period.
- TB-403 total exposure (AUC∞) after single ascending dose
- TB-403 Dose/CL after single ascending dose
- (and 3 more...)
|
36 |
All |
6 Months to 18 Years (Child, Adult) |
NCT02748135 |
ONC-403-001 |
|
May 2016 |
August 2020 |
August 2020 |
April 22, 2016 |
February 13, 2018 |
|
- Little Rock, Arkansas, United States
- Oakland, California, United States
- Hartford, Connecticut, United States
- (and 7 more...)
|
15 |
NCT03245450 |
Recruiting |
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors |
- Refractory or Recurrent Solid Tumors
- Rhabdomyosarcoma
- Non-Rhabdomyosarcoma Soft Tissue Sarcoma
|
- Drug: Eribulin mesilate
- Drug: Irinotecan hydrochloride
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1: Maximum tolerated dose (MTD) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with relapsed/refractory extra-cranial solid tumors
- Phase 1: Recommended phase 2 dose (RP2D) of eribulin mesilate in combination with irinotecan hydrochloride in pediatric participants with relapsed/refractory extra-cranial solid tumors
- Phase 2: Objective response rate (ORR)
- (and 10 more...)
|
86 |
All |
12 Months to 17 Years (Child) |
NCT03245450 |
E7389-G000-213 2016-003352-67 |
|
July 20, 2017 |
June 30, 2020 |
October 31, 2020 |
August 10, 2017 |
February 12, 2018 |
|
- Uniklinik RWTH Aachen Kinderklinik
Aachen, Germany - Charite Virchow Kinderklinik - CC17
Berlin, Germany - Uniklinik Essen AoR Kinderklinik
Essen, Germany - (and 4 more...)
|
16 |
NCT02409576 |
Recruiting |
Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas |
- Ewing Sarcoma
- Osteosarcoma
- Rhabdomyosarcoma
|
- Biological: Expanded , Activated NK cells
|
Interventional |
Phase 1 Phase 2 |
- National University Hospital, Singapore
- KK Women's and Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease response after expanded activated NK cell infusion
- Persistence and phenotype of expanded NK cells in research participants with EWS, RMS and OS.
- Toxicity of NK cells infusion (NCI toxicity criteria CTC version 4.0)
- (and 2 more...)
|
20 |
All |
up to 80 Years (Child, Adult, Senior) |
NCT02409576 |
DSRB 2014/00452 CTC1400413 (NUH) CTC1400412 (KKWCH) |
NKEXPSARC |
February 2015 |
August 2018 |
September 2018 |
April 7, 2015 |
November 6, 2017 |
|
- National University Hospital
Singapore, Singapore - KK Women's and Children's Hospital
Singapore, Singapore
|
17 |
NCT02945800 |
Recruiting |
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma |
- Osteosarcoma
- Ewing Sarcoma
- Rhabdomyosarcoma
- Soft Tissue Sarcoma
|
- Drug: nab-Paclitaxel
- Drug: Gemcitabine
|
Interventional |
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- National Pediatric Cancer Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Progression Free Survival (PFS)
- Occurrence of Study Treatment Related Adverse Events
|
72 |
All |
12 Years to 30 Years (Child, Adult) |
NCT02945800 |
MCC-18613 |
|
October 21, 2016 |
March 2020 |
March 2021 |
October 26, 2016 |
January 12, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Connecticut Children's Medical Center
Hartford, Connecticut, United States - A.I. duPont Hospital for Children, Delaware - Nemours
Wilmington, Delaware, United States - (and 10 more...)
|
18 |
NCT02048371 |
Recruiting |
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes |
- Liposarcoma
- Osteogenic Sarcoma
- Ewing/Ewing-like Sarcoma
- Rhabdomyosarcoma
|
- Drug: Regorafenib
- Drug: Placebo
|
Interventional |
Phase 2 |
- Sarcoma Alliance for Research through Collaboration
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- The progression-free survival (PFS)
- The incidence of reported CTCAE (Common Terminology Criteria for Adverse Events) version 4.03 adverse events
- Overall response rate (ORR)
- Time to tumor progression (TTP)
|
150 |
All |
5 Years and older (Child, Adult, Senior) |
NCT02048371 |
SARC024 |
|
July 2014 |
August 2020 |
December 2020 |
January 29, 2014 |
February 21, 2018 |
|
- City of Hope National Medical Center
Duarte, California, United States - Sarcoma Oncology Research Center
Santa Monica, California, United States - Stanford University
Stanford, California, United States - (and 13 more...)
|
19 |
NCT00736749 |
Recruiting |
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies |
- Acute Lymphoblastic Leukemia
- Brain Neoplasm
- Hodgkin Lymphoma
- Rhabdomyosarcoma
|
- Procedure: Assessment of Therapy Complications
- Other: Questionnaire Administration
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Collection of cumulative therapeutic exposure data
- Collection of protocol-specific outcome data
- Percentage of eligible patients located who were lost to follow-up
- (and 3 more...)
|
4485 |
All |
Child, Adult, Senior |
NCT00736749 |
ALTE05N1 NCI-2009-00382 PALTE05N1_A06PAMDREVW01 CDR0000590123 U10CA180886 U10CA098543 |
|
May 2008 |
January 2100 |
|
August 18, 2008 |
October 23, 2017 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama
Mobile, Alabama, United States - (and 159 more...)
|
20 |
NCT03478462 |
Not yet recruiting New |
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma |
- Pediatric Solid Tumor
- Pediatric Lymphoma
- Pediatric Brain Tumor
|
|
Interventional |
Phase 1 |
- Cellectar Biosciences, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with dose limiting toxicities (DLT)
- Determination of therapeutic activity of CLR 131 in children and adolescents
|
30 |
All |
2 Years to 21 Years (Child, Adult) |
NCT03478462 |
DCL-17-001 |
|
July 2018 |
September 2020 |
December 2020 |
March 27, 2018 |
March 27, 2018 |
|
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
|
21 |
NCT02013336 |
Recruiting |
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors |
- Recurrent or Refractory Solid Tumors
- Ewing Sarcoma
- Rhabdomyosarcoma
- (and 2 more...)
|
- Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
|
Interventional |
Phase 1 |
- South Plains Oncology Consortium
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the Maximum Tolerated Dose (MTD) of MM-398 in combination with intravenous cyclophosphamide by assessing the occurrence of dose limiting toxicities
- Measurement of plasma levels of study drug to determine the pharmacokinetic properties of MM-398 in combination with cyclophosphamide
|
30 |
All |
12 Months to 20 Years (Child, Adult) |
NCT02013336 |
SPOC-2012-001 |
|
December 2013 |
December 2020 |
December 2020 |
December 17, 2013 |
April 19, 2018 |
|
- University Of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States - UT Southwestern
Dallas, Texas, United States - Houston, Texas, United States
- (and 2 more...)
|
22 |
NCT02705391 |
Recruiting |
Advanced MR Imaging in Sarcoma Patients |
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Establish correlation between perfusion Magnetic Resonance imaging (MRI), 18F-flourodeoxyglucose (18F-FDG) PET activity, MRI contrast enhancement, Magnetic Resonance Elastography (MRE)
- Establish correlation between pathologic response for ES, RMS and STS
- Establish a correlation between change in perfusion and tissue stiffness with event-free survival.
- (and 2 more...)
|
60 |
All |
7 Years and older (Child, Adult, Senior) |
NCT02705391 |
15-005622 |
|
March 2016 |
January 2021 |
January 2021 |
March 10, 2016 |
February 20, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
23 |
NCT02100891 |
Recruiting |
Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors |
- Ewing Sarcoma
- Neuroblastoma
- Rhabdomyosarcoma
- (and 2 more...)
|
- Procedure: Allogeneic HCT
- Drug: Donor NK Cell Infusion
|
Interventional |
Phase 2 |
- Monica Thakar
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-control rate
- Overall survival
|
20 |
All |
Child, Adult, Senior |
NCT02100891 |
STIR Trial |
STIR |
March 2014 |
December 2019 |
December 2019 |
April 1, 2014 |
October 25, 2017 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States - Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
24 |
NCT02415816 |
Recruiting |
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas |
- Sarcoma, Bone
- Sarcoma, Soft Tissue
- Osteosarcoma
- (and 3 more...)
|
- Procedure: Diffusion Weighted Magnetic Resonance Imaging
|
Interventional |
Not Applicable |
- St. Jude Children's Research Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Proportion of participants with pediatric sarcomas whose bone/bone marrow and soft-tissue metastasis status is correctly staged with whole body DWI MRI
- The primary tumor DWI ADC and FDG PET SUVmax values at baseline and protocol driven time points up until local control
|
90 |
All |
Child, Adult, Senior |
NCT02415816 |
DWSARC NCI-2015-00290 |
|
June 5, 2015 |
March 2022 |
April 2027 |
April 14, 2015 |
January 5, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
25 |
NCT02867592 |
Recruiting |
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors |
- Adrenal Cortex Carcinoma
- Adult Alveolar Soft Part Sarcoma
- Adult Clear Cell Sarcoma of Soft Parts
- (and 30 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response assessed by Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Pharmacokinetics (PK) parameters of cabozantinib s-malate
|
146 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02867592 |
NCI-2016-01258 ADVL1622 U10CA180886 |
|
May 8, 2017 |
November 21, 2018 |
November 21, 2018 |
August 16, 2016 |
April 17, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 119 more...)
|
26 |
NCT02557854 |
Recruiting |
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors |
- Rhabdomyosarcoma
- Neuroblastoma
- Sarcoma
- (and 3 more...)
|
- Drug: Doxorubicin HCl liposomal injection
- Device: Philips Sonalleve MR-HIFU Hyperthermia
|
Interventional |
Phase 1 |
- Theodore Laetsch
- University of Texas Southwestern Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of dose limiting toxicities (DLTs) during cycle 1 of therapy with MR-HIFU hyperthermia directed liposomal doxorubicin
- Terminal half-life (T1/2) of Doxil when delivered with MR-HIFU hyperthermia
- Volume of distribution (L/m2) of Doxil when delivered with MR-HIFU hyperthermia
- (and 5 more...)
|
14 |
All |
1 Year to 40 Years (Child, Adult) |
NCT02557854 |
UTSW-HIFU-001 |
|
December 2016 |
December 2019 |
December 2020 |
September 23, 2015 |
April 10, 2018 |
|
- UT Southwestern Medical Center/Children's Medical Center
Dallas, Texas, United States
|
27 |
NCT02982941 |
Recruiting |
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors |
- Neuroblastoma
- Rhabdomyosarcoma
- Osteosarcoma
- (and 3 more...)
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of enoblituzumab.
- Peak plasma concentration
- Number of participants that develop anti-drug antibodies
- Antitumor activity of enoblituzumab
|
112 |
All |
1 Year to 35 Years (Child, Adult) |
NCT02982941 |
CP-MGA271-04 |
|
December 2016 |
February 2020 |
February 2022 |
December 6, 2016 |
March 22, 2018 |
|
- Lucile Packard Children's Hospital, Stanford
Palo Alto, California, United States - National Cancer Institute, Center for Cancer Research
Bethesda, Maryland, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States - (and 3 more...)
|
28 |
NCT03496402 |
Not yet recruiting New |
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) |
- Neuroblastoma
- Rhabdomyosarcoma
- Ewing Sarcoma Family of Tumors
- (and 3 more...)
|
- Other: Sampling on blood, bone marrow and cerebrospinal fluid
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of patients with meaningful molecular genetic alterations
- Number of patients with meaningful immunological features
- Number of patients with identification of new tumor-specific genetic characteristics during follow-up (clonal evolution)
- (and 3 more...)
|
600 |
All |
1 Year to 25 Years (Child, Adult) |
NCT03496402 |
IC 2017-02 |
MICCHADO |
April 30, 2018 |
April 1, 2025 |
April 1, 2026 |
April 12, 2018 |
April 17, 2018 |
|
- Chu D'Amiens Picardie
Amiens, France - CHU Angers
Angers, France - CHRU de Besançon - Hôpital Jean-Minjoz
Besançon, France - (and 27 more...)
|
29 |
NCT02076906 |
Recruiting |
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors |
- Relapsed Pediatric Solid Tumors
- Refractory Pediatric Solid Tumors
- Tumors Located in Bone or Soft Tissue in Close Proximity to Bone
- (and 8 more...)
|
- Device: Magnetic Resonance High Intensity Focused Ultrasound
|
Interventional |
Phase 1 |
- AeRang Kim
- Children's Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity
- Disease response
- Patient reported outcomes and quality of life measurements
- Immune Markers
|
14 |
All |
up to 30 Years (Child, Adult) |
NCT02076906 |
HIFU3917 |
|
April 2014 |
January 2019 |
January 2019 |
March 4, 2014 |
April 3, 2018 |
|
- Children's National Medical Center
Washington, District of Columbia, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
30 |
NCT02095132 |
Recruiting |
WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors |
- Childhood Central Nervous System Neoplasm
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified
- (and 3 more...)
|
- Drug: Adavosertib
- Drug: Irinotecan Hydrochloride
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) defined as the maximum doses of WEE1 inhibitor MK-1775 and irinotecan hydrochloride at which fewer than one-third of patients experience dose limiting toxicities when receiving this combination
- Pharmacokinetic (PK) parameters of WEE1 inhibitor MK-1775 in terms of systemic exposure
- PK parameters of WEE1 inhibitor MK-1775 in terms of drug clearance
- (and 3 more...)
|
154 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02095132 |
NCI-2014-00547 ADVL1312 UM1CA097452 |
|
March 27, 2014 |
April 30, 2021 |
|
March 24, 2014 |
March 22, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Children's Hospital Los Angeles
Los Angeles, California, United States - Children's Hospital of Orange County
Orange, California, United States - (and 21 more...)
|
31 |
NCT03382158 |
Recruiting |
International PPB Registry for PPB, DICER1 and Associated Conditions |
- Pleuropulmonary Blastoma
- Sertoli-Leydig Cell Tumor
- DICER1 Syndrome
- (and 10 more...)
|
|
Observational |
|
- Children's Hospitals and Clinics of Minnesota
- Children's Research Institute
- Washington University School of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Event-free survival
- Overall response to chemotherapy
- Overall survival
- (and 4 more...)
|
100 |
All |
Child, Adult, Senior |
NCT03382158 |
FDAAA |
|
December 6, 2016 |
December 6, 2023 |
December 6, 2026 |
December 22, 2017 |
December 22, 2017 |
|
- Children;s Minnesota
Minneapolis, Minnesota, United States
|
32 |
NCT03221400 |
Recruiting |
PEN-866 in Patients With Advanced Solid Malignancies |
- Carcinoma
- Sarcoma
- Rhabdomyosarcoma
- (and 9 more...)
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Dose-Limiting Toxicities (DLTs)
- Incidence of treatment related adverse events
- Objective response rate (ORR) of tumors using RECIST 1.1 criteria
- (and 6 more...)
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03221400 |
PEN-866-001 |
|
August 29, 2017 |
December 2019 |
June 2020 |
July 18, 2017 |
April 20, 2018 |
|
- Sarah Cannon Reasearch Institute at HealthONE
Denver, Colorado, United States - National Institutes of Health / National Cancer Institute
Bethesda, Maryland, United States - Tennessee Oncology
Nashville, Tennessee, United States
|
33 |
NCT03233204 |
Recruiting |
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 29 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (complete response/partial response) determined using Response Evaluation Criteria in Solid Tumors version 1.1
- Progression free survival (PFS)
- Incidence of toxicity evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Pharmacokinetics (PK) of olaparib
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03233204 |
NCI-2017-00766 APEC1621H U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 28, 2017 |
April 19, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 63 more...)
|
34 |
NCT03213704 |
Recruiting |
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 33 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Larotrectinib
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Progression free survival
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213704 |
NCI-2017-01264 APEC1621A U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
April 17, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 64 more...)
|
35 |
NCT03213678 |
Recruiting |
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 32 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: PI3K/mTOR Inhibitor LY3023414
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression free survival (PFS)
- Pharmacokinetic (PK) parameters
|
144 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213678 |
NCI-2017-01249 APEC1621D U10CA180886 |
|
July 31, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
April 19, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 67 more...)
|
36 |
NCT03210714 |
Recruiting |
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 29 more...)
|
- Drug: Erdafitinib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression free survival (PFS)
- Pharmacokinetic (PK) parameters
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03210714 |
NCI-2017-01159 APEC1621B U10CA180886 UM1CA081457 |
|
November 6, 2017 |
December 31, 2024 |
December 31, 2024 |
July 7, 2017 |
April 19, 2018 |
|
- Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - Southern California Permanente Medical Group
Downey, California, United States - (and 51 more...)
|
37 |
NCT03155620 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 32 more...)
|
- Procedure: Biopsy
- Procedure: Biospecimen Collection
- Drug: Ensartinib
- (and 10 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (complete response/partial response) assessed according to Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of toxicity assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Incidence of research biopsy related target toxicity
- (and 2 more...)
|
1500 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03155620 |
NCI-2017-01251 APEC1621SC U10CA180886 |
|
July 24, 2017 |
September 30, 2027 |
September 30, 2027 |
May 16, 2017 |
April 19, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 90 more...)
|
38 |
NCT00565903 |
Recruiting |
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome |
- Pleuropulmonary Blastoma
- Cystic Nephroma
- Sertoli-Leydig Cell Tumor of Ovary
- (and 7 more...)
|
|
Observational |
|
- D. Ashley Hill, M.D.
- Children's Research Institute
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Identify the genetic factors which contribute to the development or progression of pleuropulmonary blastoma
- Define the clinical features of the pleuropulmonary blastoma (PPB) familial cancer syndrome.
|
2000 |
All |
up to 95 Years (Child, Adult, Senior) |
NCT00565903 |
05-0192 / 201012830 |
PPB |
March 2005 |
December 2018 |
December 2020 |
November 30, 2007 |
July 19, 2017 |
|
- Children's National Medical Center
Washington, D.C., District of Columbia, United States
|
39 |
NCT02689336 |
Recruiting |
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors |
- Glioma
- Rhabdomyosarcoma
- Osteosarcoma
- (and 5 more...)
|
- Biological: Erlotinib
- Drug: Temozolomide
|
Interventional |
Phase 2 |
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Time to progression
- Toxicities of treatment regimen
|
30 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02689336 |
201604002 |
|
August 6, 2016 |
November 30, 2019 |
May 31, 2020 |
February 23, 2016 |
February 15, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
40 |
NCT02536183 |
Recruiting |
A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors |
- Pediatric Cancer
- Solid Tumors
- Rhabdomyosarcoma
- (and 7 more...)
|
- Device: Magnetic resonance high intensity focused ultrasound
- Drug: Lyso-thermosensitive liposomal doxorubicin
|
Interventional |
Phase 1 |
- AeRang Kim
- Children's Research Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of LTLD
- Toxicity profile of LTLD
- Pharmacokinetics of LTLD
- (and 4 more...)
|
34 |
All |
up to 30 Years (Child, Adult) |
NCT02536183 |
HIFU Thermodox |
|
October 2016 |
October 2018 |
October 2020 |
August 31, 2015 |
April 2, 2018 |
|
- Children's National Medical Center
Washington, District of Columbia, United States
|
41 |
NCT01661400 |
Recruiting |
Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors |
- Glioma
- Neuroectodermal Tumors, Primitive
- Wilms Tumor
- (and 4 more...)
|
- Drug: Metronomic Cyclophosphamide
- Drug: Thalidomide
|
Interventional |
Early Phase 1 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety
- Toxicity
- Radiographic marker of neovascularization
- Best overall response
|
12 |
All |
6 Months to 21 Years (Child, Adult) |
NCT01661400 |
201209088 |
ASCR |
October 2012 |
February 2018 |
February 2021 |
August 9, 2012 |
November 21, 2017 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
42 |
NCT03220035 |
Recruiting |
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 22 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Vemurafenib
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR)
- Progress free survival (PFS)
- Incidence of adverse events evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03220035 |
NCI-2017-01244 APEC1621G U10CA180886 |
|
July 24, 2017 |
December 31, 2023 |
December 31, 2023 |
July 18, 2017 |
April 19, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 62 more...)
|
43 |
NCT01505569 |
Recruiting |
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors |
- Ewing's Family Tumors
- Renal Tumors
- Hepatoblastoma
- (and 9 more...)
|
- Drug: Ifosfamide
- Drug: Etoposide
- Drug: Mesna
- (and 9 more...)
|
Interventional |
Not Applicable |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Number of Patients Who Achieved Transplant Engraftment
- Disease Free Survival
- Treatment-Related Mortality
|
20 |
All |
up to 70 Years (Child, Adult, Senior) |
NCT01505569 |
2011OC057 MT2011-09C |
|
October 20, 2011 |
January 2019 |
January 2021 |
January 6, 2012 |
December 5, 2017 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
44 |
NCT03050268 |
Recruiting |
Familial Investigations of Childhood Cancer Predisposition |
- Acute Leukemia
- Adenomatous Polyposis
- Adrenocortical Carcinoma
- (and 43 more...)
|
|
Observational |
|
- St. Jude Children's Research Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Identification of novel cancer predisposing genes
|
3000 |
All |
Child, Adult, Senior |
NCT03050268 |
SJFAMILY |
SJFAMILY |
April 6, 2017 |
March 31, 2037 |
March 31, 2037 |
February 10, 2017 |
January 5, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
45 |
NCT02890758 |
Recruiting |
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 |
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Acute Lymphoblastic Leukemia
- (and 11 more...)
|
- Biological: Natural Killer (NK) Cells
- Biological: ALT803
|
Interventional |
Phase 1 |
- David Wald
- Case Comprehensive Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients without Graft Versus Host Disease (GVHD)
- Number of patients with hematological response
- Patients response for radiographically measurable lesions
- (and 10 more...)
|
54 |
All |
18 Years and older (Adult, Senior) |
NCT02890758 |
CASE2Z16 |
|
January 10, 2018 |
August 2019 |
August 2019 |
September 7, 2016 |
January 23, 2018 |
|
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
46 |
NCT02624388 |
Recruiting |
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) |
- Lymphoma
- Childhood Lymphoma
- Solid Tumor
- (and 13 more...)
|
- Drug: Genistein
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- Time to neutrophil count recovery following myelosuppressive chemotherapy
- Serum marker levels of inflammation during cycles of chemotherapy
- Number of days that participants experience adverse events that are commonly caused by chemotherapy treatment
- (and 12 more...)
|
50 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02624388 |
17588 |
UVA-Gen001 |
August 2016 |
August 2018 |
June 2019 |
December 8, 2015 |
June 21, 2017 |
|
- University of Virginia
Charlottesville, Virginia, United States
|
47 |
NCT02508038 |
Recruiting |
TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate |
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Hodgkin Lymphoma
- (and 8 more...)
|
- Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT
- Drug: Zoledronate
|
Interventional |
Phase 1 |
- University of Wisconsin, Madison
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of acute graft versus host disease (GVHD)
- Incidence of neutrophil engraftment
- Incidence of platelet engraftment
- (and 4 more...)
|
21 |
All |
7 Months to 21 Years (Child, Adult) |
NCT02508038 |
UW13090 NCI-2015-01163 |
|
January 2016 |
May 2018 |
November 2020 |
July 24, 2015 |
April 19, 2017 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
48 |
NCT02390843 |
Recruiting |
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors |
- Retinoblastoma
- Clear Cell Sarcoma
- Renal Cell Carcinoma
- (and 9 more...)
|
- Drug: Simvastatin
- Drug: Cyclophosphamide
- Drug: Topotecan
- Drug: Myeloid growth factor
|
Interventional |
Phase 1 |
- Emory University
- Children's Healthcare of Atlanta
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Simvastatin
- Number of Dose-Limiting Toxicities (DLTs)
- Percentage of Participants With Overall Tumor Response (Response Rate)
- (and 5 more...)
|
36 |
All |
1 Year to 29 Years (Child, Adult) |
NCT02390843 |
IRB00078790 |
AflacST1402 |
February 2015 |
February 2019 |
February 2021 |
March 18, 2015 |
August 7, 2017 |
|
- Children's Healthcare of Atlanta/Emory University
Atlanta, Georgia, United States
|
49 |
NCT01336803 |
Recruiting |
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI |
- Bone Cancer
- Chondrosarcoma
- Ewing's Sarcoma
- (and 5 more...)
|
- Drug: Feraheme
- Procedure: MR Scan
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- all cause mortality
- Differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced MRI.
|
50 |
All |
8 Years to 40 Years (Child, Adult) |
NCT01336803 |
PEDSBONE0006 SU-04062011-7666 |
|
August 2011 |
December 2018 |
December 2019 |
April 18, 2011 |
January 17, 2018 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
50 |
NCT02162732 |
Recruiting |
Molecular-Guided Therapy for Childhood Cancer |
- Neuroblastoma
- Medulloblastoma
- Glioma
- (and 16 more...)
|
|
Interventional |
Not Applicable |
- Giselle Sholler
- Translational Genomics Research Institute
- Dell, Inc.
- Spectrum Health Hospitals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic sequencing using predictive modeling to make real-time treatment decisions for children with relapsed/refractory cancers.
- Number of Participants with Adverse Events as a Measure of Safety
- Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.
- (and 3 more...)
|
200 |
All |
13 Months to 21 Years (Child, Adult) |
NCT02162732 |
NMTRC009 |
|
June 2014 |
June 2020 |
June 2021 |
June 13, 2014 |
July 11, 2017 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Rady Children's Hospital
San Diego, California, United States - Connecticut Children's Hospital
Hartford, Connecticut, United States - (and 16 more...)
|